Ovarian Cancer Clinical Trial

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Summary

This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject is ≥18 to 75 years of age at the time of signing the study informed consent.
Subject has histologically confirmed diagnosis of any one of the indicated tumor types
Subject is HLA-A*02 positive. (This determination will be made under screening protocol ADP-0000-001).
Subject's tumor shows expression of the MAGE-A4 RNA or protein. (This determination will be made under screening protocol ADP-0000-001).
Adequate organ function as indicated in the study protocol
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
Subject meets disease-specific requirements per protocol

7. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.

Exclusion Criteria:

Subject does not express appropriate HLA-A genotype
Subject is receiving excluded therapy/treatment per protocol
Subject has symptomatic CNS metastases.
Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illness.
Subject has active infection with HIV, HBV, HCV or HTLV
Subject is pregnant or breastfeeding.

Additional Exclusion Criteria for the Radiation Substudy:

Subject does not meet eligibility criteria for the main study (ADP-0044-001).
Subject does not have at least one target lesion amenable to radiation.
Certain radiation therapy within 6 months of clinical trial are an exclusion.
Metastatic disease impinging on the spinal cord or threatening spinal cord compression.

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT03132922

Recruitment Status:

Active, not recruiting

Sponsor:

Adaptimmune

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT03132922

Recruitment Status:

Active, not recruiting

Sponsor:


Adaptimmune

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.